US EditionA Heart Disease Cure For Pericarditis? Phase 3 Trial Advances | David Elsley – Cardiol Therapeutics
Summary by The Deep Dive
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
A Heart Disease Cure For Pericarditis? Phase 3 Trial Advances | David Elsley – Cardiol Therapeutics
FULL DISCLOSURE: This is sponsored content for Cardiol Therapeutics. Discover the major breakthrough at Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) as CEO David Elsley reveals the enrollment of their first patient in the pivotal Phase 3 MAVERIC trial for recurrent pericarditis. In this concise interview, Elsley discusses how their oral drug therapy aims to prevent new episodes of this debilitating heart condition, the impressive Phase 2 resu…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
